spinal muscular atrophy

Biohaven fails phase 3 SMA test but plans talks with FDA, plots move into obesity
Fierce Biotech
Mon, 11/25/24 - 11:22 am
Biohaven
taldefgrobep alfa
SMA
spinal muscular atrophy
FDA
obesity
Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial
Clinical Trials Arena
Tue, 10/15/24 - 10:16 am
Roche
SMA
spinal muscular atrophy
Evrysdi
clinical trials
Biogen fills in some of the blanks on its trial of a high-dose version of Spinraza
Fierce Pharma
Wed, 10/9/24 - 09:52 am
Biogen
SMA
spinal muscular atrophy
Spinraza
Scholar Rock scores with ‘surprise’ success in SMA drug study
BioPharma Dive
Mon, 10/7/24 - 11:52 am
Scholar Rock
SMA
spinal muscular atrophy
apitegromab
obesity
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Fierce Pharma
Wed, 09/4/24 - 10:49 pm
Biogen
Spinraza
SMA
spinal muscular atrophy
Spinal muscular atrophy market to reach $3bn across 7MM by 2033
Clinical Trials Arena
Wed, 07/17/24 - 09:12 pm
SMA
spinal muscular atrophy
PTC to sell spinal muscular atrophy drug royalties for $1B
BioPharma Dive
Thu, 10/19/23 - 11:34 am
PTC Therapeutics
spinal muscular atrophy
Evrysdi
Royalty Pharma
Spinal Muscular Atrophy: Four trials to watch over the next 12 months
Clinical Trials Arena
Fri, 08/11/23 - 11:39 am
clinical trials
spinal muscular atrophy
Scholar Rock
apitegromab
Novartis
Zolgensma
Spinraza
clenbuterol
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk
BioSpace
Mon, 07/3/23 - 11:38 am
Genentech
spinal muscular atrophy
SMA
Evrysdi
Novartis sales of Zolgensma gene therapy slow as market shifts
BioPharma Dive
Tue, 10/25/22 - 11:02 pm
Novartis
gene therapy
spinal muscular atrophy
SMA
Zolgensma
Novartis reports deaths of two patients treated with Zolgensma gene therapy
BioPharma Dive
Thu, 08/11/22 - 11:32 pm
Novartis
gene therapy
Zolgensma
SMA
patient deaths
spinal muscular atrophy
Scholar Rock in a hard place as biotech lays off 25% of staff, narrows pipeline and loses CMO
Fierce Biotech
Tue, 05/17/22 - 10:45 am
Scholar Rock
layoffs
spinal muscular atrophy
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
BioSpace
Fri, 04/29/22 - 10:30 am
Genentech
Evrysdi
risdiplam
SMA
spinal muscular atrophy
Biogen Announces New Spinraza Data Ahead of Presentation
BioSpace
Mon, 03/14/22 - 11:39 pm
Biogen
Spinraza
SMA
spinal muscular atrophy
New Data Reinforces Impact of Novartis' Gene Therapy on SMA
BioSpace
Mon, 03/14/22 - 10:46 am
Novartis
gene therapy
spinal muscular atrophy
Zolgensma
Roche's aim to widen Evrysdi's label nabs speedy FDA review in young spinal muscular atrophy patients
Fierce Pharma
Tue, 01/25/22 - 10:54 am
Roche
Evrysdi
risdiplam
FDA
spinal muscular atrophy
Biogen brings in a successor to Spinraza
BioPharma Dive
Tue, 01/4/22 - 10:49 pm
Biogen
Ionis Pharmaceuticals
Spinraza
BIIB115
antisense
spinal muscular atrophy
Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there?
Fierce Pharma
Fri, 10/22/21 - 12:39 pm
Novartis
Europe
Zolgensma
SMA
spinal muscular atrophy
Roche builds evidence for Evrysdi’s benefits in younger SMA patients
Pharmaforum
Fri, 09/24/21 - 12:01 pm
Roche
spinal muscular atrophy
Evrysdi
Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial
Fierce Pharma
Thu, 09/16/21 - 10:52 am
Biogen
Spinraza
SMA
Roche
Evrysdi
spinal muscular atrophy

Pages